This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ‘good science, good ethics, and good business,’ one expert said.
Medscape Medical News